Yavuz, CelalCaliskan, AhmetYazici, SuleymanKarahan, OguzGuclu, OrkutDemirtas, Sinan2024-04-242024-04-2420121840-2291https://hdl.handle.net/11468/20969Background: Human ischemia modified albumin (IMA) provides diagnostic and prognostic information for acute coronary ischemia. However, its role in peripheral ischemic disorders is unclear. The aim of this study is to detect the association between ischemia duration and the discriminator value of serum IMA levels in rat model with created peripheral ischemia. Methods: Thirty-two male Sprague-Dawley rats were included in the study. The rats were divided into four equal groups. The rats in Group I were sacrificed to determine the basal serum values of IMA without any application. The rats in Group II, the sham group, were applied with simple femoral incision only. The rats in Group III and IV had their common femoral artery clamped with classic femoral incision. Blood samples were taken after 120 minutes of ischemia in Group III and after 360 minutes of ischemia in Group IV, respectively. The serum ischemia modified albumin levels were detected using the blood samples. The results were compared statistically. Results: Obtained IMA levels were similar in the sham (Group II) and baseline (Group I) groups (p>0.05). The serum IMA levels were determined as 33 +/- 4 (33) mu/L, 36 +/- 9 (34) mu/L and 57 +/- 19 (61) mu/L in Groups I, III and IV, respectively. High IMA levels were found in advanced ischemia duration. The increase in serum IMA levels with time was statistically significant as can be seen in Figure 1 (p<0.05). Conclusion: Peripheral ischemic disorders can cause extremity loss if not treated immediately. In addition, delayed treatments may have fatal results. Therefore, timing is important in such cases. We suggest that serum IMA levels may be beneficial for the determination of ischemia duration in peripheral ischemia. They may also improve the predictive values of other standard biomarkers of ischemia.eninfo:eu-repo/semantics/closedAccessHuman Ischemia Modified AlbuminPeripheral IschemiaBiomarkerTreatment TimingArticle61034783481WOS:0003121583000352-s2.0-84871226520N/AN/A